

Beslut vid Fru Berta Kamprads styrelsemöte 25 april 2022

Gabriel Adrian, FBKS-2022-31

Hypoxia as a predictive marker for individualized radiotherapy

Anslag beviljat: 2022-2023

Sara Alkner, FBKS-2022-6

The T-REX trial: Tailored regional radiotherapy using gene expression profiling in clinically node-negative breast cancer patients with 1-2 sentinel node macrometastases

Anslag beviljat: 2022-2025

Elsa Arbajian, FBKS-2022-38

Increased understanding of lung cancer biology through organoid modelling

Anslag beviljat: 2022-2024

Christer Ceberg, FBKS-2022-41

Translational image-guided radiotherapy - strengthening the growing user community at the XenX facility

Anslag beviljat: 2022-2023

Maria Gebre-Medhin, FBKS 2022-26

ARTSCAN VI - a multicentre phase III study of risk-based treatment intensification with hyperfractionated radiotherapy in head and neck cancer patients

Anslag beviljat: 2022-2025

Rasmus Green, FBKS-2022-1

Endometrial cancer specific survival model development using pooled population-based consecutive cohorts and external validation - Multicentric study based on individual patient clinical and laboratory data

Anslag beviljat: 2022-2023

Gabriella Honeth, FBKS-2022-36

Validating potential targets for novel therapeutic intervention in endocrine-resistant metastatic breast cancer

Anslag beviljat: 2022-2023

Axel Hyrenius Wittsten, FBKS-2022-9

Boosting the Therapeutic Potential of Engineered T cells

Anslag beviljat: 2022-2025

Helena Jernström, FBKS-2022-19

Investigation into the role of Caveolin-1 as potential prognostic and treatment predictive marker in Triple Negative Breast Cancer (TNBC)

Anslag beviljat: 2022-2023

Karin Jirström, FBKS-2022-5

On-treatment biomarkers in Colorectal cancer for Life: The On-CALL study
Anslag beviljat: 2022-2023

Anna Karlsson, FBKS-2022-14

Validation of a prognostic predictor preceding an interdisciplinary clinical trial in lung cancer
Anslag beviljat: 2022

Siker Kimbung, FBKS-2022-35

Defining early biomarkers of response to preoperative chemotherapy and unravelling the molecular and histopathological landscape of “normal-like” breast cancers.
Anslag beviljat: 2022-2023

Jenny Klintman, FBKS-2022-29

Real-world analyzes of treatment outcome and quality of life aspects in Swedish subjects with chronic lymphocytic leukemia (CLL)
Anslag beviljat: 2022-2023

Thomas Laurell, FBKS-2022-34

Unbiased label-free isolation of circulating tumor cells in local recurrent breast cancer - A benchmarking study of microfluidic CTC acoustophoresis vs. CellSearch® -
Anslag beviljat: 2022-2025

Alexandra Lindblad, FBKS-2022-17

MCL limited - a population-based study of treatment strategies in patients with limited stage or indolent mantle cell lymphoma diagnosed in Sweden and United Kingdom 2006-2018
Anslag beviljat: 2022-2023

Malin Lindstedt, FBKS-2022-8

Myeloid cell molecular programs that shape head and neck tumor immunity
Anslag beviljat: 2022-2025

Malin Malmsjö, FBKS-2022-21

Developing Photoacoustic Imaging into a Novel Diagnostic Tool for Malignant Melanoma
Anslag beviljat: 2022-2024

Pia Maly Sundgren, FBKS-2022-23

Replacement preclinical SPECTCT at LBIC, Medical Faculty, LU
Anslag beviljat: 2022-2023

Selamawit Mekuria, FBKS-2022-24

Developing Photoacoustic Imaging into a Novel Diagnostic Tool for Malignant Melanoma
Anslag beviljat: 2022-2024

Mef Nilbert, FBKS-2022-27

Precision diagnostics and treatment of hereditary and sporadic colorectal cancer
Anslag beviljat: 2022-2025

Martin Nilsson, FBKS-2022-3

Improved radiotherapy for anal cancer
Anslag beviljat: 2022-2023

Emma Niméus, FBKS-2022-7

Low risk profile for de-escalation of adjuvant treatment in breast cancer patients with high long-term survival despite omission of axillary clearance
Anslag beviljat: 2022-2023

Helena Persson, FBKS-2022-10

Estrogen receptor alpha in breast cancer - one gene, multiple proteins, many functions
Anslag beviljat: 2022-2025

Bengt Phung, FBKS-2022-42

Mapping melanoma cell states using spatial analyses and determining clinical relevance
Anslag beviljat: 2022-2023

Elisabeth Rasmusson, FBKS-2022-37

Quality-of- Life after curative treatment of Head & Neck Cancer
Anslag beviljat: 2022-2023

Ann Rosendahl, FBKS-2022-43

Novel positioning of biomarkers from obesity to breast cancer
Anslag beviljat: 2022

Lisa Rydén, FBKS-2022-20

A comprehensive fingerprint of the primary tumor for prediction of nodal metastasis in breast cancer
Anslag beviljat: 2022-2023

Johanna Sjövall, FBKS-2022-39

Analysis of HPV DNA in plasma in HPV positive patients with oropharyngeal cancer - a prospective study of HPV DNA levels for treatment response and surveillance
Anslag beviljat: 2022-2025

Sven-Erik Strand, FBKS-2022-11

Understanding radiobiological mechanism based on a new method to determine tumor absorbed dose for more accurately determine dose effect relationship
Anslag beviljat: 2022-2023

Anders Wittrup, FBKS-2022-40

Next generation super-resolution imaging infrastructure at the Kamprad facility for cancer research
Anslag beviljat: 2022-2025